信达生物：玛仕度肽获国家药监局批准用于成人2型糖尿病患者血糖控制

Core Viewpoint - The announcement indicates that Innovent Biologics has received approval from the National Medical Products Administration (NMPA) in China for the new drug application (NDA) of its dual receptor agonist, Masituzumab injection, for the treatment of blood sugar control in adult patients with type 2 diabetes [1] Group 1 - Innovent Biologics announced the approval of Masituzumab injection for a second indication [1] - The drug is a dual receptor agonist targeting glucagon (GCG) and glucagon-like peptide-1 (GLP-1) [1] - The approval is specifically for use in adult patients with type 2 diabetes [1]